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1. Introduction 
Churg–Strauss syndrome (CSS) is a rare disease characterized by allergic granulomatosis 
and necrotizing vasculitis following peripheral blood eosinophilia and eosinophilic tissue 
infiltration (Churg & Strauss, 1951). CSS is classified as a vasculitis of small and medium-
sized arteries (Jennette & Falk, 1995), although the vasculitis is not often apparent in the 
initial phases of the disease. It occurs mainly in adults, almost always in patients with a 
history of bronchial asthma, and is associated with chronic rhinosinusitis. The most 
frequently affected organs are the lungs and the ear, nose, and throat (ENT) system, 
followed by the skin. Involvement of the cardiac and gastrointestinal tract systems 
determines the prognosis. Nonspecific immunosuppressive therapy with corticosteroids 
(CSs), cyclophosphamide (CYC) and other drugs produces good responses initially in most 
patients, but relapses are frequent, especially in the early disease phase, and morbidity and 
mortality remain important problems. Our research has explored the etiology of CSS by use 
of HLA analysis and has shown that the clinical and immunological manifestations of 
asthma occur in the pre-vasculitic phase of the disease. Our work further indicates that 
treatment, especially in the form of intravenous immunoglobulin (IVIG), is beneficial.  
2. Clinical manifestations, mechanisms, and treatment 
2.1 Etiology and genetic factors 
The precise etiologies of CSS and the role played by genetic factors remain unknown. In 
some CSS patients, vasculitis is apparent within a few weeks or months of exposure to 
putative triggers, such as rapid discontinuation of oral corticosteroids, vaccination, 
desensitization, viral infection, or medication with leukotriene receptor antagonists. 
Although there are some reports of genetic factors, such as the IL10.2 haplotype (Vaglio et 
al., 2007) and HLA (human leukocyte antigen)-DPB1 (Wieczorek et al., 2008), influencing 
susceptibility to CSS, to date there is no compelling evidence supporting the involvement of 
such factors. Familial cases of systemic vasculitis associated with p-ANCA (p-antineutrophil 
cytoplasmic antibody)-positive vasculitis or Wegener’s granulomatosis (WG) have been 
reported, but there have been no reports of familial CSS, excluding cases of familial 
vasculitis with CSS and WG in two first-degree relatives. We presented the first case of 
familial CSS in two sisters with atopic-type bronchial asthma and negativity for p-ANCA 
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(Tsurikisawa et al., 2007). The two sisters had seven siblings, for a total of four females and 
five males. Eight were still alive, but both parents were dead. The parents had no known 
history of atopy, and of the siblings only another sister, the oldest, also had bronchial 
asthma and atopy. We analyzed human leukocyte antigen (HLA)-A, HLA-B, HLA-DRB1, 
HLA-DQA1, HLA-DQB1, and HLA-DPB1 in the two CSS sisters and their six living siblings 
(Table 1). All four sisters, including the two CSS sisters, had HLA-A02, HLA-B48, DRB1-15, 
DQA1-01, DQB1-06, and DPB1-20; all four brothers had HLA-A20, HLA-B39, DRB1-04, 
DQA1-03, DQB1-03, and DPB1-04. Testing revealed no significant differences in the 
frequencies of any of the HLAs (P = 0.102–0.67). Our results and accumulated clinical 
evidence indicate that CSS is not a heritable disease.  
 
 HLA-A HLA-B DRB1 DQA1 DQB1 DPB1 
Patient 1 02 24 48 52 15 15 01 01 06 06 20 09 
Patient 2 02 02 48 40 15 09 01 03 06 03 20 05 
Sister 1 02 24 48 52 15 15 01 01 06 06 20 09 
Sister 2 02 02 48 40 15 90 01 03 06 30 20 05 
Brother 1 20 24 39 52 15 04 01 03 06 03 05 09 
Brother 2 20 24 39 52 15 04 01 03 06 03 05 09 
Brother 3 20 02 39 40 90 04 03 03 30 03 05 05 
Brother 4 20 24 39 52 15 04 01 03 06 03 05 09 
Table 1. HLA typing of two CSS patients and their siblings. 
2.2 Clinical manifestation of vasculitis 
CSS is a rare disorder characterized by an incidence of 0.11 to 2.66 new cases per million 
population per year and an overall prevalence of 10.7 to 14 per 1,000,000 adults (Gatenby, 
2009; Mahr, 2004; Mohammad 2007). The male-to-female ratio ranges from 0.3 to 2.3 and the 
mean age at onset reported in the literature varies from 38 to 52 years (range 7–74 years) 
(Kahn 2008; Sinico & Bottero, 2009). Nonetheless, there is a generally agreed-upon clinical 
description of the disease. The frequencies of organ involvement and other clinical features 
of CSS previously reported by others and observed at our hospital are summarized in Table 
2. CSS has been traditionally induced in ANCA-associated vasculitis, WG, and microscopic 
polyangiitis (MPA). The prevalence of ANCAs in CSS is less consistent than in WG or MPA, 
being reported in approximately 40% of cases (Guillevin et al., 1999; Kahn et al., 2008; 
Pagnoux & Guillevin, 2010; Sinico & Bottero, 2009). Recently, it was shown that different 
clinical phenotypes could be observed according to the presence or absence of ANCA, 
thereby suggesting that there are varying disease mechanisms in the pathogenesis of CSS. 
Increased prevalence of central nervous system involvement (Keogh & Speck, 2003), renal 
involvement, peripheral neuropathy, and pulmonary hemorrhage (Sinco et al., 2005) has 
been reported among ANCA-positive patients. Negative ANCA status is associated with 
heart disease and lung involvement (Sinco et al., 2005). From these findings, it has been 
hypothesized that, as in WG and MPA, ANCAs may contribute directly to the endothelial 
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vasculitic damage seen in ANCA-positive patients, whereas in ANCA-negative patients 
eosinophils may be directly responsible for the release of cationic proteins and eosinophil-
derived neurotoxin (Kallenberg, 2005). These data suggest that CSS, when presenting as a 
form of necrotizing small-vessel vasculitis, is a true ANCA-associated disease, characterized 
by positivity for myeloperoxidase (MPO)-ANCAs. Alternatively, ANCA-negative patients 
may be clinically characterized by tissue infiltration by eosinophils that results in fibrotic 
organ damage; their disease may belong more to the spectrum of hypereosinophilic 
syndromes rather than to the spectrum of ANCA vasculitis. The existence of two clinical 
phenotypes may reveal different pathways of pathogenicity in CSS. 
 
 Churg Chumbley Lanham Hashimoto Guillevin 
Our 
cases 
 USA USA UK Japan France Japan 
 1951 1977 1984 1994 1999 2011 
Cases 13 30 138 87 96 86 
M/F 4/9 21/9 72/66 41/46 45/51 27/59 
Age mean 33 47 38 47 48 53.4 
Age range (7–62) (15–69)  (17–79) (17–74) (19–83) 
Clinical manifestations(%)      
Asthma 100 100 100 93 100 100 
Pulmonary 
infiltrates 
39 27 74 33 38 80 
Nose, ear, throat 77 70 69  48 91 
Multiplex 
mononeuritis 
69 63 64 65 78 99 
Gastrointestinal 92 17 62 19 33 85 
Heart 54 16 52 33 30 74 
Arthritis 31 20 46 52 41 42 
Myalgias   33 51 54 25 
Skin  66 51    
Purpura 62  46 44 31 67 
Nodules 54 27 33 27 19 6 
Renal 31 20 46 46 16 58 
Central nervous 
system 
61  27  8 18 
Table 2. Clinical manifestation of vasculitis 
www.intechopen.com
 
Advances in the Etiology, Pathogenesis and Pathology of Vasculitis 
 
238 
2.3 Mechanisms and clinical manifestations of the pre-vasculitic phase of CSS as an 
asthmatic phase 
Asthma is present in 96% to 100% of CSS patients and is the cardinal feature of CSS. Asthma 
may precede systemic vasculitis by approximately 8 years and, in some cases, by more than 30 
years (Chumbley et al., 1977; Churg & Strauss, 1951; Guillevin et al., 1999; Lhote & Guillevin, 
1995). The precise etiology of CSS and the asthmatic phase that precedes it, as well as the role 
of genetic factors, remains unknown. We demonstrated in a retrospective cohort study that the 
clinical manifestations of asthma occur in the pre-vasculitic phase of the disease (Tsurikisawa 
et al., 2007). The asthma of 87.5% of 24 patients in the pre-vasculitic phase of CSS at their first 
hospital visit was severe. It was characterized in 42.9% of these patients by a need for 
treatment with systemic steroids and mechanical ventilation and by the presence of sinusitis in 
57.1% during the period from the first hospital visit to the onset of CSS (P < 0.0001) (Table 3). 
 
Characteristic 
Non-CSS severe 
asthma 
Severe asthma 
pre-CSS 
 
 N = 130 (44.2%) N = 21 (87.5%) P-value 
Systemic corticosteroid 
treatment 
N = 9 (6.9%) N = 9 (42.9%) <0.0001 
Corticosteroid dose (in 
mg, converted to the 
prednisolone equivalent) 
5.3±2.0 7.2±3.6 N.S 
Inhaled corticosteroid 
dose (in µg, converted to 
the beclomethasone 
equivalent) 
1194.7±575.1 1371.4±721.9 N.S 
Intubation N = 2 (1.5%) N = 3 (14.3%) 0.0018 
Sinusitis N = 40 (30.8%) N = 12 (57.1%) <0.0001 
Table 3. Differences between non-CSS (Churg-Strauss syndrome) severe asthma and severe 
asthma in the pre-vasculitic phase of CSS. 
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Fig. 1. Total numbers of white blood cells (WBC) (A)s and percentages of eosinophils (B) in 
the peripheral blood of all patients at the first hospital visit. The percentage of eosinophils in 
the peripheral blood of pre-CSS asthma patients was significantly higher than that in other 
asthma patients. † P < 0.01. NS: not significant. 
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The percentage of eosinophils in the peripheral blood of pre-CSS asthmatics at the first 
hospital visit was also significantly higher than that in non-CSS asthmatics (P < 0.01) (Fig. 
1).Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic value 
of the percentage of eosinophils in the peripheral blood for predicting future onset of CSS. The 
area under the curve was 0.8992 (95% CI = 0.825–0.973). A reasonably high specificity (99.4%) 
and a high sensitivity (66.7%), with a cut-off point of 20%, were obtained (Fig. 2).  
 
Specificity
Sensitivity 20%
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 0.2 0.4 0.8 1.00.6
20%
 
Fig. 2. ROC curve for evaluating the value of the percentage of eosinophils in the peripheral 
blood as a predictor of future onset of CSS 
The percentage forced expiratory volume (%FEV1) in the severe asthmatics and the 
asthmatic patients who later developed CSS was lower than that in patients with mild or 
moderate asthma (p < 0.01). The %FEV1 in the asthmatic patients who later developed CSS 
was the same as that in patients with severe asthma (Fig. 3). However, bronchial 
hyperresponsiveness (BHR) to acetylcholine (ACh) in the pre-vasculitic patients was 
significantly less severe than that in the non-CSS patients with severe asthma (P < 0.01) and 
was as mild as that in patients with mild asthma (Fig. 4). Thus, asthma severity in the pre-
vasculitic phase of CSS is related to airflow limitation and to eosinophilic inflammation in 
the peripheral blood, but not to BHR, which may occur as a result of airway vasculitis. We 
propose that asthma patients who develop CSS differ from other asthma patients, from 
whom they can be differentiated at the first hospital visit by evaluating these factors.  
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Fig. 3. FEV1 (% predicted) at the first hospital visit in all patients.  
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The %FEV1 was measured at the first hospital visit in asthmatic patients (mild, moderate, 
severe) and in those who later developed CSS. The %FEV1 in the severe asthmatics and the 
asthmatic patients who later developed CSS was lower than in patients with mild asthma (P 
< 0.01). However, the %FEV1 in the asthmatic patients who later developed CSS was the 
same as that in patients with severe asthma.† P < 0.01. * P < 0.05. NS: not significant. 
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Fig. 4. Bronchial hyperresponsiveness (BHR) to inhaled Ach in all patients within 1 month of 
the first hospital visit. 
Modified box plots represent the distribution of BHR to inhaled Ach in asthmatic patients 
(mild, moderate, severe) and pre-CSS asthma patients within 1 month of the first hospital 
visit. † Mann-Whitney Test, P < 0.01. NS: not significant. 
Eosinophilic infiltrations, such as those found in chronic eosinophilic pneumonia (CEP) and 
eosinophilic gastroenteritis, precede systemic vasculitis in half of all patients with CSS 
(Lhote & Guillevin, 1995; Steinfeld et al., 1994). Some clinicians suggest that patients with 
CEP following asthma are more likely to develop CSS if the CEP is left untreated (Churg, 
2001). However, some patients in whom asthma is complicated by CEP do not develop CSS. 
There is no clear mechanism that explains why some CEP patients with asthma develop 
CSS, whereas others do not. The etiology of idiopathic CEP is not understood, although in 
some cases CEP is caused by infection with a parasite, virus, or fungus or by drugs, toxic 
agents, or radiation therapy (Cottin & Cordier, 2005; Marchand & Cordier, 2006). Asthma 
occurs before CEP in about half to two-thirds of CEP patients (Cottin & Cordier, 2005; 
Marchand & Cordier 2006). Increasing numbers of eosinophils and lymphocytes in the 
peripheral blood and bronchoalveolar lavage fluid (BALF) contribute to the development of 
CEP. There are many mediators of eosinophilia in CEP, including regulated upon activation 
normal T-cell-expressed and -secreted (RANTES), eotaxin, thymus- and activation-regulated 
chemokine (TARC/CCL17), and cytokines, including IL-2, IL-3, IL-5, IL-10, IL-13, and IL-18. 
The number of CD4+CD25+ T cells in the BALF and peripheral blood is increased in patients 
with CEP (Albera, 1995). By contrast, peripheral blood mononuclear cells in patients with 
CSS secrete not only the type 1 cytokine IFN-, but also type 2 cytokines, such as IL-4, IL-13, 
and, in particular, IL-5.  
T-regulatory (Treg) cells play essential roles in maintaining immunologic homeostasis, 
preventing autoimmunity, and providing peripheral tolerance to antigens, including 
autoantigens and allergens. Treg cells, including Tr1 (T-regulatory cells type 1), CD4+CD25+, 
Th3, and natural killer (NK) T cells, all suppress effector T cells of either the Th1 or Th2 
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phenotype, which are involved in mediating inflammation (Jonuleit et al., 2002; Sakaguchi, 
2000; Weiner, 2001). CD4+CD25+ cells are naturally occurring T-regulatory (nTreg) cells that 
are defined as CD25hi CD127low FOXP3+ (Roncarolo & Battaglia, 2007). nTreg cells mediate 
their suppressive effects through cell contact. Tr1 cells are antigen-specific populations 
derived from conventional CD4+CD25– naïve precursors following exposure to antigen 
under conditions of limiting costimulation, such as with IL-10, immature dendritic cells, or 
dexamethasone. The mechanism by which Tr1 cells exert suppression appears to be 
mediated by secretion of suppressor cytokines, such as IL-10 and TGF-. Recent studies 
have focused on the role of Treg cells in human diseases such as systemic lupus 
erythematosus, rheumatoid arthritis, cancer, Guillain–Barré syndrome, multiple sclerosis, 
infection, and asthma. However, whether Treg cell activity is involved in the mechanism and 
etiology of CSS is not known. We examined the phenotypes and functions of CD4+CD25+ T 
cells from asthma patients with CEP and from CSS patients at disease onset and after 
therapy, and we compared our findings with those in patients with general asthma. We  
found that, at disease onset, CSS patients, unlike CEP patients, had significantly fewer  
CD4+CD25+ T cells than patients with any type of asthma (steps 1–4) (Saito et al., 2008; 
 
 Normal 
controls 
 (n = 9) 
Bronchial asthma 
CSS at 
onset  
CEP at 
onset  Step 1 Step 2 Step 3 Step 4 
Blood 
eosinophils 
 (no. of cells) 
161.9± 
65.0 
209.4± 
168.3 
290.6± 
209.8 
357.3± 
215.5 
380.0± 
517.0 
8042.6± 
6559.3†&†† 
3762.6± 
2310.3† 
CD4+CD25+ (%) 
31.4± 
8.2‡ 
52.2± 
12.2 
52.6± 
11.8 
46.2± 
6.6 
42.7± 
10.3* 
34.9± 
15.6†&†† 
48.1± 
11.6 
IL-5 in 
CD4+CD25+ (%) 
0.0± 
0.0 
4.4± 
6.6 
5.2± 
10.1 
6.2± 
10.8 
4.1± 
7.4 
14.6± 
11.9††† 
11.2± 
12.5†††† 
IL-10 in 
CD4+CD25+ (%) 
0.0± 
0.0 
4.7± 
7.5 
4.9± 
6.3 
1.1± 
2.2 
2.7± 
4.4 
0.3± 
1.0** 
20.9± 
17.0†&†† 
IL-10 in 
CD4+CD25– (%) 
0.5± 
1.2 
0.5± 
1.5 
0.4± 
0.6 
0.2± 
0.5 
0.3± 
0.5 
0.1± 
0.1 
6.6± 
11.4†&†† 
TGF- in 
CD4+CD25+ (%) 
0.0± 
0.0‡‡ 
6.7± 
10.0 
4.4± 
6.9 
2.8± 
5.0 
2.6± 
5.9 
1.0± 
0.9‡‡‡ 
6.7± 
10.5†† 
IL-2 in 
CD4+CD25– (%) 
26.3± 
25.8 
35.1± 
17.9 
32.4± 
22.3 
23.1± 
21.2 
17.0± 
16.5*** 
7.6± 
7.2‡‡‡ 
22.0± 
17.0†† 
Table 4. Eosinophil counts and cytokines in CD25+ or CD25- CD4+ T cells in normal controls, 
patients with asthma (as classified by the US National Institutes of Health and National 
Asthma Education and Prevention Program), patients with chronic eosinophilic pneumonia 
(CEP), and patients with Churg-Strauss syndrome (CSS)  
† CSS or CEP vs. control and Step 1 and Step 2 and Step 3 and Step 4: P < 0.01; †† CSS vs. CEP: P < 0.01; 
††† CSS vs. control and Step 1 and Step 2 and Step 4: P < 0.01, vs. Step 3: P < 0.05; †††† CEP vs. control: 
P < 0.01, vs. Step 1 and Step 2 and Step 4: P < 0.05; * Step 4 vs. Step 1 and Step 2: P < 0.01; **: CSS vs. 
Step 1 and Step 2: P < 0.05;  
*** Step 4 vs. Step 1: P < 0.01, vs. Step 2: P < 0.05; ‡ control vs. Step 1 and Step 2 and Step 3 and CEP: P < 
0.01, vs. Step 4: P < 0.05; ‡‡ control vs. Step 1 and Step 2 and Step 3 and Step 4 and CEP: P < 0.01; ‡‡‡ 
CSS vs. Step 1 and Step 2: P < 0.01 
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Tsurikisawa et al., 2008)(Table 4). CD4+CD25+ T cells producing IL-10 were rarely detected 
in CSS patients at disease onset or relapse, whereas the numbers of IL-10–producing T cells 
in CEP patients were high at disease onset. Fewer CD4+CD25– T cells producing IL-2 were 
found in CSS patients before treatment than were found in CEP patients at disease onset (P 
< 0.01) (Table 4). The proportions of CD4+CD25+ T cells producing IL-10 and of CD4+CD25– 
T cells producing IL-2 in CSS patients significantly increased at remission after treatment (P 
< 0.01) (Fig 5). We confirmed that maintenance of the numbers of Treg cells in asthma 
patients with CEP may inhibit CSS development via the action of cytokines, such as IL-10 
and IL-2, produced by CD4+CD25+ and CD4+CD25– T cells, respectively. 
In contrast, the CD4+CD25+ T cell count in patients with CEP at onset was the same as that 
in asthmatics at every step of asthma (Table 4) and did not change even with improvement 
of the disease (Fig. 5). The CD4+CD25+ T cell count in patients with CSS significantly 
increased with either relapse or remission after treatment, and this increase was significantly 
greater in patients in remission than in those who relapsed (P < 0.01) (Fig. 5). Moreover, 
when we compared the intracellular cytokine levels of IL-10 and TGF- with the serum 
levels of IL-10 (all patients assayed: <2.0 pg/mL) and TGF- (all patients assayed: <8.0 
pg/mL) , we found that the serum IL-10 levels were extremely low in all patients with 
asthma, CSS, and CEP. There was not significant the serum IL-10 level among three groups. 
It is not clear why there were no significant differences among the serum levels of these 
cytokines yet there were significant differences among the intracellular levels. 
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Fig. 5. Percentages of CD4+ among CD25+ T cells in patients with CSS and CEP at disease 
onset and after treatment. Median values are shown by horizontal bars. Differences between 
patient groups were evaluated by using the Mann–Whitney U test. † P < 0.01. * P < 0.05. NS: 
not significant. 
The number of CD4+CD25+ T cells producing IL-5, which causes eosinophilia in peripheral 
blood cells and lung tissue, was high in CSS and CEP patients at disease onset and 
decreased significantly after treatment of CSS and improvement of CEP (Fig. 6a). 
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CD4+CD25+ T cells producing IL-10 were rarely detected in patients with CSS at onset or in 
those who relapsed. However, when patients with CSS achieved clinical remission after 
treatment, the number of CD4+CD25+ T cells producing IL-10 significantly increased 
compared with the number at onset. The number of CD4+CD25+ T cells producing IL-10 in 
patients with CEP was high at disease onset and decreased significantly after improvement 
of eosinophilic pneumonia (Fig. 6(b)). The number of CD4+CD25– T cells producing IL-2 in 
patients with CSS at onset was significantly less than that in patients with CEP at onset.  
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(a) IL-5 in CD4+CD25                                 (b) IL-10 in CD4+CD25+ 
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(c) IL-2 in CD4+CD25- 
Fig. 6. (a) Percentages of CD4+CD25+ T cells producing IL-5; (b) CD4+CD25+ T cells 
producing IL-10; and (c) CD4+CD25– T cells producing IL-2 in patients with CSS or CEP at 
disease onset and after treatment. Median values are shown by horizontal bars. Differences 
between patient groups were evaluated by using the Mann–Whitney U test. † P < 0.01. * P < 
0.05. NS: not significant. 
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After treatment, CSS patients who achieved remission showed a significant increase in the 
number of CD4+CD25– T cells producing IL-2, to the level seen in CEP patients at disease 
onset, but there was no change in the count of CD4+CD25– T cells producing IL-2 in patients 
with CEP between disease onset and improvement (Fig. 6c). The number of organs involved 
was significantly negatively correlated with the percentage of CD4+CD25+ T cells at onset, 
remission, and relapse in CSS patients (r = –0.51, P < 0.01, Fig. 7). The percentage of CD25+ 
CD4+ T cells was correlated with IL-10 production in all patients with stable asthma and in 
those with CSS or CEP at onset (R = 0.42, P < 0.01; data not shown). These results show that 
the CD4+CD25+ T cells producing IL-10 were Tr1 cells.  
Dysregulated production of IL-17 is associated with human autoimmune diseases, including 
multiple sclerosis, inflammatory bowel disease, and psoriasis. CD4+ T cells that produce IL-
17 represent a distinct lineage (Th17) that produces neither IL-4 nor IFN-. Recently, a 
relationship between Treg cells and Th17 in the pathogenesis of some human autoimmune 
diseases was reported (Lock C et al 2002, Fujino et al 2003,  Vaknin-Dembinsky A et al 2006, 
Zheng et al 2007). 
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Fig. 7. Correlation between percentage of CD25+ CD4+ T cells and the degree of organ 
involvement. “Organ involvement” included asthma, sinusitis, pulmonary infiltration, 
mononeuritis multiplex or polyneuropathy, arthritis, tympanitis, lymphadenitis, mastitis, or 
involvement of the myocardium, gastrointestinal tract, kidney, skin, central nervous system, 
eye, gallbladder, or liver. Open circles represent patients with CSS at onset, open triangles 
represent patients with CSS who relapsed after an initial remission, and open squares 
represent patients with CSS in remission after treatment. A significant linear relationship is 
evident (r = –0.51, P < 0.01) for all patient groups. 
We confirmed that the percentage of CD4+ T cells producing IL-17 was significantly greater 
in patients with active CSS than in healthy control patients or in patients with asthma, BA + 
CEP, or inactive CSS (Fig. 8) (Saito et al., 2009). Moreover, the percentage of CD4+ T cells 
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Fig. 8. Increased ability of CD4+ T cells from active CSS patients to produce IL-17. 
producing IL-17 in active CSS who were at onset or at relapse was significantly greater than 
those in inactive CSS and the percentage of CD4+CD25+ T cells producing IL-10 (Tr1 cells) 
in active CSS significantly decreased than those in inactive CSS who achieved remission 
after treatment (Tr 1) (Fig. 9) (Saito et al., 2009). Th17 cells were identified as CD4+ T cells 
that produced mainly IL-17 and IL-22. Eosinophilia is a characteristic of CSS, and some 
reports suggest that the IL-25 produced by eosinophils promotes innate adaptive immunity 
by enhancing Th2 cytokine production (Terrier et al., 2010). We showed that the number of 
CD4+ T cells producing IL-17 or IL-22 in the peripheral blood of CSS patients increased at  
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Fig. 9. Th17 or Tr1 cells representing CD4+CD25+ T cells that produce IL-17 or IL-10 in 
relation to disease activity in CSS patients. * * P < 0.01, * P < 0.05. 
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relapse and that the numbers of these CD4+ T cells were correlated with the number of 
CD4+ T cells producing IL-25 (Fig.10) (Saito et al., 2011). Indoleamine 2, 3-dioxygenase 
(IDO) expression in monocytes from all CSS patients was positively correlated with the 
percentage of CD4+CD25+ Treg cells producing IL-10 and inversely correlated with the 
percentage of Th17 cells (Fig. 11) (Saito et al., 2011). Thus CSS relapse may be linked to 
elevated levels of CD4+ T cells producing IL-25, which promote Th2 inflammation and 
reduce Tr1 cell subpopulations, which also result from lower IDO expression in monocytes. 
Thus, the percentages of CD4+CD25+ Treg cells producing IL-10 and of Th17 cells reflect the 
disease activity of CSS (Fig. 11). 
Mononuclear leukocytes derived from patients from each group were stimulated with PMA 
and ionomycin in the presence of 10 g/mL of brefeldin A to generate and accumulate IL-
17. Statistical significance was tested using the Mann-Whitney U test. * * P < 0.01, * P < 0.05, 
NS: not significant. 
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Fig. 10. Correlation between IL-25 and Th17 cell generation.  
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Fig. 11. Monocyte IDO expression and CD4+CD25+ T cells that producing IL-10 and Th17 
cell detection. 
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We found a positive correlation between the percentage of CD4+ T cells producing IL-25 and 
the percentage of CD4+ T cells producing IL-17 (a) or IL-22 (Fig. 9b) in relapsed CSS patients. 
The increase in IL-25 may be linked to increased Th17 cell generation.  
IDO expression in monocytes from all CSS patients was positively correlated with the 
detection frequency of CD4+CD25+ T cells that producing IL-10and inversely correlated with 
the detection frequency of Th17 cells.  
2.4 Treatment 
The mainstay of treatment for CSS is systemic CS therapy. Additional treatments with 
immunosuppressive agents, such as CYC or azathioprine, may be used in some patients. 
Other treatment options include methotrexate, mycophenolate mofetil, rituximab, 
interferon-alpha, anti-IgE therapy, anti-IL-5 antibodies, anti-TNF-alpha (infliximab, 
etanercept, adalimumab), plasma exchange, and intravenous immunoglobulin (IVIG). 
Corticosteroids and immunosuppressants, especially CYC, have improved considerably 
most symptoms of vasculitis, particularly those involving the gastrointestinal system, skin, 
and lungs, as well as constitutional symptoms. However mononeuritis multiplex and heart 
failure in patients with CSS or ANCA-associated systemic vasculitis do not respond to 
combination therapy with CS and CYC (Abril et al., 2003; Hattori et al., 1999; Renaldini et 
al., 1993; Sehgal et al., 1995). IVIG therapy has been used to treat various diseases, including 
MPA, WG, and ANCA-associated systemic vasculitis (Jayne et al., 1991; Lockwood, 1996; 
Richter et al., 1995). Hamilos and Christensen were the first to report that eosinophilia in 
CSS is improved by treatment with IVIG (Hamilos & Christensen, 1991), and other 
investigators have since described successful treatment with IVIG of CSS itself (Armentia et 
al., 1993; Levy et al., 1999). We previously reported (Tsurikisawa et al., 2004) that IVIG 
therapy improved mononeuritis multiplex or heart failure in 14 of 15 patients with CSS who 
did not respond to combination therapy with CS and CYC. IVIG (400 mg) was given daily 
for 5 days. Neuropathy was evaluated by assessing manual muscle strength and skin 
temperature at affected sites. Cardiac function was evaluated by using ejection fraction 
assessment with echocardiography and two imaging tests of the myocardium (123I-meta-
iodobenzylguanidine (MIBG) and 201Tl). Peripheral eosinophil counts and CD69 expression 
on the surfaces of eosinophils were also examined. We found that manual muscle strength 
improved and the skin temperature of both hands and legs significantly increased on IVIG 
therapy (Fig. 12). In the five patients with heart failure, the ejection fraction of the left 
ventricle significantly increased from 35.2% to 61.0% (Fig. 13). Myocardial uptake of 
123MIBG significantly  increased, indicating improved myocardial viability (Fig. 14). 201Tl 
images showed a perfusion defect and, following IVIG therapy, improved blood perfusion. 
IVIG therapy did not, however, affect the peripheral blood eosinophil count, but it did 
downregulate the expression of CD69 (Fig. 15). This finding suggests that, in CSS, activated 
eosinophils survive even after CS or CYC treatment, and that IVIG therapy decreases the 
number of activated eosinophils that express early activation markers such as CD69. The 
progression of CSS may, therefore, be related more to the abundance of CD69-expressing 
eosinophils than to the total number of eosinophils. Thus, one mechanism by which IVIG 
therapy acts on CSS may be the inactivation of eosinophils. IVIG therapy may induce 
remission by ameliorating neuropathy and heart failure in those patients who are 
unresponsive to treatment with CSs or CYC. 
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Fig. 12. Manual muscle test. “Before therapy” indicates before treatment with corticosteroid 
or cyclophosphamide or both; before IVIG and after IVIG indicate before and after high-
dose intravenous immunoglobulin therapy, respectively. 
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Fig. 13. Ejection fraction as measured by using echocardiography. EF, ejection fraction 
Image analysis of MIBG was performed on the regions over the whole left ventricular 
myocardium and the upper mediastinal area. The heart to mediastinum (H/M) ratio was 
then determined from the cardiac 123I-MIBG images. The washout rate of MIBG within the 
myocardium was measured as a percent change in the left ventricular activity from early to 
delayed images within the left ventricular regions. 
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Fig. 14. The heart to mediastinum (H/M) ratio (A) and washout rate (B) of 123I-MIBG in 
patients with heart failure. 
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Fig. 15. Effect of intravenous immunoglobulin (IVIG) on CD69+ eosinophil production. 
However, administration of IVIG alone, without concomitant treatment with CSs and CYC 
as an initial treatment approach for CSS, did not improve vasculitic symptoms in various 
organs, including the digestive tract, skin and pulmonary infiltration. Furthermore, it had 
no effect on peripheral nerve damage, cardiac dysfunction, the number of eosinophils 
(including CD69+CCR3+-activated eosinophils), or the proportion of eosinophils with 
vacuole formation in white blood cells. This suggests that CS administration reduces 
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eosinophil counts but does not reduce the percentage of activated eosinophils, and that IVIG 
administered with CSs may exhibit an adjuvant effect. IVIG should, therefore, not be used in 
place of conventional therapy with CSs or immunosuppressants such as CYC, except when 
patients are resistant to CS and CYC therapy (Guillevin & Pagnoux, 2003). 
After treatment with CSs, immunosuppressants, or IVIG therapy, paralysis—presenting as 
multiple mononeuropathy—often remains. We consider rehabilitation for multiple 
mononeuropathy just as important as the therapeutic management of these patients. We 
found that application of transdermal isosorbide dinitrate (ISDN) patches to the toes of the 
affected leg or hand produced warming and improved numbness (Fig. 16) (Tsurikisawa et 
al., 2003). Application of ISDN patches to the affected leg or hand also increased the skin 
temperature, not only on the affected side but also on the contralateral site. The mechanism 
involves an increase in blood flow, via local and systemic vasodilating effects, in the region 
where the ISDN patches are applied; this reduces hyperalgesia and blocks neurogenic 
inflammation, leading to improved nerve conduction by increasing neuronal postsynaptic 
cyclic GNP levels. 
 
32.7℃ 25.7℃ 35.1℃ 35.8℃
Without ISDN patches
With ISDN patches
on the affected side
Peripheral skin 
temperature 
 
Fig. 16. Skin temperature after application of ISDN patches to an affected leg. The skin 
temperature increased not only in the affected leg, but also on the contralateral side.  
2.5 Prognosis 
Before the use of CSs, the mortality rate of CSS was approximately 50% within 3 months of 
diagnosis (Gayraud et al., 2001; Guillevin et al., 1999). Other reports suggest a 5-year 
survival rate for CSS of 62% to 80% (Chumbley et al., 1977; Gayraud et al., 2001; Guillevin et 
al., 1996; Lane et al., 2005). Most deaths result from complications of the vasculitic phase of 
the disease and are due to cardiac failure or myocardial infarction, cerebral hemorrhage, 
renal failure, gastrointestinal bleeding, or status asthmaticus. The presence or absence of the 
features that make up the five-factor score (FFS) [cardiac involvement, gastrointestinal 
disease (bleeding, perforation, infarction or pancreatitis), renal insufficiency (creatinine 
concentration >1.6 mg/dl; proteinuria >1 g/day), and central nervous system involvement] 
has been used to predict survival in CSS (Gayraud et al., 2001; Guillevin et al., 1996). Of the 
five elements of the FFS, cardiac involvement and gastrointestinal disease appear to be the 
strongest indicators of poor prognosis (Guillevin et al., 1999). According to published 
reports, the remission rate in CSS ranges from 81% to 91% and the relapse rate ranges from 
20% to 60% (Mukhtyar et al., 2008; Pavone et al., 2006. Gastrointestinal involvement, ANCA 
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persistent positivity, and a rise in ANCA titer are also risk factors for relapse. We reported 
that cardiac sympathetic nerve function was damaged in CSS patients with cardiac 
involvement and that 123I-MIBG scintigraphy was useful for detecting cardiac involvement 
and predicting cardiac events (Horiguchi et al., 2011). 123I-MIBG scintigraphy was 
performed in 28 patients with CSS, 12 of whom had cardiac involvement, and the early and 
delayed heart to mediastinum ratio (early H/M and delayed H/M) and washout rate were 
calculated. We found that early H/M and delayed H/M were significantly lower, and the 
washout rate was significantly higher, in patients with cardiac involvement than in control 
patients and those without cardiac involvement (early H/M, P = 0.0024, P = 0.0001; delayed 
H/M, P = 0.0002, P = 0.0001; washout rate, P = 0.0012, P = 0.0052; vs. those without cardiac 
involvement and vs. control patients, respectively). Accuracy in detecting cardiac 
involvement was 86% for delayed H/M and the washout rate and 79% for early H/M and 
B-type natriuretic peptide (BNP). Kaplan-Meier analysis showed significantly lower cardiac-
event-free rates in patients with early H/M ≤2.18 and BNP >21.8 pg/mL than in patients 
with early H/M >2.18 and BNP ≤21.8 pg/mL (log rank test P = 0.006). 
3. Conclusion 
A prognosis of CSS suggests a 5-year survival rate in the range of 62% to 80%, which is far 
from ideal. CSS involves multilateral systemic vasculitis that shares many clinical 
characteristics with other ANCA-associated vasculitides, potentially causing a necrotizing 
process that can involve any organ or system. The clinical features of CSS reflect the 
pathogenic role of peripheral blood and tissue hypereosinophilia, which can directly 
contribute to damage of primary organs. These two aspects of the disease complicate 
diagnosis and the initiation of pharmacologic treatment. The mainstay of treatment for CSS 
is CSs or CYC or both; however, patients with CSS who experience mononeuritis multiplex 
or heart failure do not respond to combination therapy with CSs and CYC. We 
recommended IVIG therapy, in addition to conventional therapy, for CSS patients with 
severe neuropathy or heart failure who fail to respond to combination therapy with CSs and 
CYC. IVIG treatment not only decreases the number of activated eosinophils expressing 
CD69+CCR3+ but also could reduce the amount of CS needed for maintenance of remission 
in CSS (Danieli et al. 2004). Increased availability of novel therapies for CSS, together with a 
better understanding of the pathogenesis of the disease, should improve the long-term 
management of this condition. 
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